Androgenic alopecia drug market was estimated at $1.23 billion in 2025 and is expected to grow to $2.22 billion by 2035, registering a CAGR of 6.1% over the forecast period from 2026 to 2035. The global androgenic alopecia drug market is expanding as the underlying condition becomes increasingly prevalent with age and across populations. Up to half of adult men and women experience noticeable pattern hair loss as they age, driven by a genetic predisposition and sensitivity to androgens that progressively miniaturizes hair follicles. This widespread occurrence has elevated diagnostic rates and early intervention, pushing more patients toward established pharmacological treatments such as finasteride and minoxidil that slow progression and support regrowth. Broader recognition of the impact of hair loss on psychological well-being and quality of life is driving more individuals to seek clinical solutions, reinforcing demand for drug-based therapies globally.
Browse the full report description of “Androgenic Alopecia Drug Market Size, Share & Trends Analysis Report by Drug Type (Finasteride, Minoxidil, Dutasteride, Spironolactone, and Other Drug-Based Therapies), by Route of Administration (Oral, Topical, Injection, and Other Routes), by End User (Hospitals, Clinics, and Homecare), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/androgenic-alopecia-drug-market
Globally, approximately 50 million men and 30 million women in the US alone are affected by androgenetic alopecia, illustrating the extensive patient base for therapeutic intervention. By age 70, up to 80% of men and 50% of women develop some degree of hair loss, reflecting a significant age-related burden that sustains demand for drug treatments across the lifespan. Clinical data also indicate that a substantial proportion of adults show progressive hair thinning well before middle age, contributing to early treatment uptake and longer treatment duration. These figures underscore both the scale of the affected population and the persistent need for effective pharmaceutical solutions.
Recent Product Development, Clinical Progress, and Strategic Investments in the Androgenic Alopecia Drug Market
- October 2025 – Pelage Pharmaceuticals funding milestone: Pelage Pharmaceuticals secured USD 120 million in a Series B financing round led by Arch Venture Partners and Google Ventures. The capital is intended to support the advancement of PP405, a topical small-molecule therapy aimed at reactivating dormant hair follicle stem cells to promote natural hair regrowth. Following an earlier Series A raise of USD 16.75 million in February, the company is preparing to initiate a Phase 3 clinical trial for androgenetic alopecia in 2026.
- January 2025 – Eirion Therapeutics clinical progress: Eirion Therapeutics reported positive outcomes from its first-in-human clinical trial of ET-02, a topical drug candidate developed for androgenic alopecia associated with age-related hair loss. These results represent an important step toward further clinical development of a novel pharmacological treatment option.
- July 2024 – Kintor Pharmaceutical topical product launch: Kintor Pharmaceutical introduced a topical anti-hair loss product for androgenetic alopecia formulated with its internally developed compound KX-826. The product launch followed the receipt of International Nomenclature Cosmetic Ingredient approval, with KX-826 positioned as a topical androgen receptor antagonist targeting localized hair loss pathways.
- February 2024 – Kintor Pharmaceutical clinical trial approval: Kintor Pharmaceutical announced that China’s NMPA approved a Phase Ib/III clinical study evaluating KX-826 in combination with minoxidil for the treatment of male androgenetic alopecia. The trial is designed to assess both safety and efficacy, supporting the company’s strategy to position KX-826 as a core drug asset within its hair loss portfolio.
- March 2023 – Sun Pharmaceutical strategic acquisition: Sun Pharmaceutical Industries Limited completed the acquisition of Concert Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company. The acquisition added deuruxolitinib, an oral JAK1/2 inhibitor under development for alopecia conditions, strengthening Sun Pharma’s dermatology and hair loss drug pipeline.
Market Coverage
- The market number available for – 2025-2035
- Base year- 2025
- Forecast period- 2026-2035
- Segment Covered-
- Drug Type
- Route of Administration
- End User
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape – Cipla Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., among others.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Androgenic Alopecia Drug Market Report Segment
By Drug Type
- Finasteride
- Minoxidil
- Dutasteride
- Spironolactone
- Other Drug-Based Therapies
By Route of Administration
- Oral
- Topical
- Injection
- Other Routes
By End User
Global Androgenic Alopecia Drug Market Report Segment by Region
North America
Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- ASEAN Economies
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/androgenic-alopecia-drug-market